An open-label, non-randomized, pharmacokinetic and safety study of multiple oral doses of GW679769 in subjects with hepatic impairment.
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Casopitant (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2008 Actual start date changed from Apr 2006 to Dec 2005 as reported by Clinicaltrials.gov.
- 04 Dec 2007 Status changed from recruiting to completed.